| Systematic dissection of the metabolic-apoptotic interface in AML reveals heme biosynthesis to be a regulator of drug sensitivity KH Lin, A Xie, JC Rutter, Y Ahn, JM Lloyd-Cowden, AG Nichols, ... Cell metabolism 29 (5), 1217-1231. e7, 2019 | 88 | 2019 |
| Using antagonistic pleiotropy to design a chemotherapy-induced evolutionary trap to target drug resistance in cancer KH Lin, JC Rutter, A Xie, B Pardieu, ET Winn, RD Bello, A Forget, ... Nature genetics 52 (4), 408-417, 2020 | 54 | 2020 |
| Cancer cells depend on environmental lipids for proliferation when electron acceptors are limited Z Li, BW Ji, PD Dixit, K Tchourine, EC Lien, AM Hosios, KL Abbott, ... Nature metabolism 4 (6), 711-723, 2022 | 29 | 2022 |
| UBR5 forms ligand-dependent complexes on chromatin to regulate nuclear hormone receptor stability JM Tsai, JD Aguirre, YD Li, J Brown, V Focht, L Kater, G Kempf, ... Molecular Cell 83 (15), 2753-2767. e10, 2023 | 14 | 2023 |
| The folate cycle enzyme MTHFR is a critical regulator of cell response to MYC-targeting therapies A Su, F Ling, C Vaganay, G Sodaro, C Benaksas, R Dal Bello, A Forget, ... Cancer discovery 10 (12), 1894-1911, 2020 | 14 | 2020 |
| P2RY2-AKT activation is a therapeutically actionable consequence of XPO1 inhibition in acute myeloid leukemia KH Lin, JC Rutter, A Xie, ST Killarney, C Vaganay, C Benaksas, F Ling, ... Nature cancer 3 (7), 837-851, 2022 | 13 | 2022 |
| FALCON systematically interrogates free fatty acid biology and identifies a novel mediator of lipotoxicity N Wieder, JC Fried, C Kim, EH Sidhom, MR Brown, JL Marshall, ... Cell metabolism 35 (5), 887-905. e11, 2023 | 7 | 2023 |
| Induced protein degradation for therapeutics: past, present, and future H Yoon, JC Rutter, YD Li, BL Ebert The Journal of Clinical Investigation 134 (1), 2024 | 3 | 2024 |
| Exploration of the Tunability of BRD4 Degradation by DCAF16 Trans-labelling Covalent Glues MM Hassan, YD Li, MW Ma, M Teng, WS Byun, K Puvar, R Lumpkin, ... BioRxiv, 2023 | 3 | 2023 |
| Selinexor in combination with induction and consolidation therapy in older adults with AML is highly active TS Pardee, KC Wood, KH Lin, J Rutter, M Pierobon, E Petricoin, S Lyerly, ... Blood 134, 1388, 2019 | 3 | 2019 |
| A new anticancer strategy based on inhibiting mitochondrial proline dehydrogenase (PRODH) and exploiting synthetic lethal interactions with p53 restoration and/or glutaminase … GK Scott, J Rutter, K Frazier, D Rothschild, C Yau, C Benz Cancer Research 75 (15_Supplement), 5402-5402, 2015 | 2 | 2015 |
| Compositions and methods for sensitizing acute myeloid leukemias to chemotherapy K Wood, KH Lin, J Rutter, XH Ang US Patent App. 17/927,575, 2023 | 1 | 2023 |
| Mediator Kinase Inhibition Impedes Transcriptional Plasticity and Prevents Resistance to ERK/MAPK-Targeted Therapy in KRAS-Mutant Cancers DP Nussbaum, CA Martz, AM Waters, A Barrera, JC Rutter, ... bioRxiv, 2022.09. 17.508384, 2022 | 1 | 2022 |
| Mediator Kinase Inhibition Impedes Transcriptional Plasticity and Prevents Resistance to ERK/MAPK-Targeted Therapy in KRAS-Mutant Cancers K Wood, D Nussbaum, C Martz, A Waters, A Barrera, J Rutter, ... Research Square, 2023 | | 2023 |
| UBR5 Is a Hect E3 Ubiquitin Ligase That Regulates Chromatin Bound Nuclear Hormone Receptor Stability JM Tsai, JD Aguirre, J Brown, V Focht, YD Li, G Kempf, L Kater, P Galli, ... Blood 140 (Supplement 1), 2968-2969, 2022 | | 2022 |
| The folate cycle enzyme MTHFR is a critical regulator of cell response to MYC-targeting therapies. AF Dal Bello, B Pardieu, KH Lin, JC Rutter, F Christopher, LB Fenouille, ... | | |
